Amundi Purchases 512,883 Shares of Amgen Inc. $AMGN

Key Points

• Amundi increased its Amgen stake by 15.2% in the second quarter, purchasing 512,883 shares to hold 3.89 million shares worth approximately $1.41 billion. Institutional investors collectively own 76.5% of Amgen.
• Amgen reported quarterly earnings of $6.29 per share and revenue of $10.05 billion, exceeding analyst expectations, while raising its 2026 outlook. The company also declared a quarterly dividend of $2.52 per share, representing a 2.3% annualized yield.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and a $381.68 price target. Positive developments for Repatha and investigational obesity drug MariTide are offset by regulatory pressure surrounding Tavneos and continued insider selling.

Amundi raised its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 15.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,890,189 shares of the medical research company's stock after purchasing an additional 512,883 shares during the quarter. Amundi owned 0.72% of Amgen worth $1,408,715,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Groupe la Francaise boosted its stake in Amgen by 647.8% in the 2nd quarter. Groupe la Francaise now owns 1,361 shares of the medical research company's stock worth $493,000 after purchasing an additional 1,179 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Amgen in the second quarter worth $29,326,000. California State Teachers Retirement System boosted its position in shares of Amgen by 36,047.1% during the second quarter. California State Teachers Retirement System now owns 298,255,793 shares of the medical research company's stock worth $108,004,388,000 after acquiring an additional 297,430,677 shares during the last quarter. Ameritas Advisory Services LLC boosted its position in shares of Amgen by 139.3% during the second quarter. Ameritas Advisory Services LLC now owns 14,119 shares of the medical research company's stock worth $5,113,000 after acquiring an additional 8,220 shares during the last quarter. Finally, Wedmont Private Capital grew its stake in Amgen by 2.7% during the second quarter. Wedmont Private Capital now owns 8,666 shares of the medical research company's stock valued at $3,149,000 after acquiring an additional 231 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Rachna Khosla sold 1,252 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 over the last three months. 0.85% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AMGN. Royal Bank Of Canada lifted their price target on shares of Amgen from $370.00 to $400.00 and gave the company an "outperform" rating in a report on Wednesday, August 5th. Morgan Stanley restated an "overweight" rating and set a $362.00 price objective on shares of Amgen in a research report on Wednesday, August 19th. UBS Group lifted their target price on Amgen from $420.00 to $440.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Daiwa Securities Group decreased their target price on Amgen from $410.00 to $390.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 13th. Finally, Oppenheimer lifted their price objective on Amgen from $400.00 to $450.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Amgen has a consensus rating of "Hold" and a consensus price target of $381.68.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha data could expand its addressable market. Amgen reported that Repatha reduced all-cause mortality by 20% in a prespecified analysis of the Phase 3 VESALIUS-CV trial, which studied more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. Earlier use could support broader adoption of the cardiovascular drug. Amgen Repatha VESALIUS-CV article
• Positive Sentiment: MariTide retains a potential convenience advantage in obesity treatment. Amgen’s investigational therapy could require less-frequent dosing than competing treatments from Eli Lilly and Novo Nordisk. That feature may help differentiate MariTide if its clinical and regulatory profile supports approval, although competition in the market remains intense. Amgen MariTide obesity article
• Neutral Sentiment: Shares had recently approached a 52-week high. Recent strength followed better-than-expected quarterly earnings and raised 2026 guidance, but the stock’s elevated valuation and gains left it more vulnerable to profit-taking when adverse regulatory news emerged. Amgen stock and 2026 guidance article
• Negative Sentiment: U.K. action against Tavneos intensified regulatory risk. The U.K. regulator suspended Tavneos for new patients and indicated a path toward revoking its authorization in March 2027, saying the drug’s benefit-risk balance was no longer favorable and that its pivotal efficacy study could not be relied upon. This compounds the FDA’s April proposal to withdraw U.S. approval over effectiveness, application-disclosure and liver-safety concerns, raising the possibility of broader loss of value for the drug. Amgen Tavneos regulatory pressure article
• Negative Sentiment: Insider selling added a modest sentiment headwind. Reported insider transactions showed seven sales and no purchases over the past six months, though these trades are less significant than the Tavneos developments. Amgen trading disclosures article

Amgen Price Performance

Shares of AMGN opened at $437.23 on Monday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The business has a fifty day moving average of $397.39 and a 200 day moving average of $367.14. The company has a market cap of $236.38 billion, a PE ratio of 27.17, a P/E/G ratio of 3.15 and a beta of 0.43. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $447.03.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion for the quarter, compared to analysts' expectations of $9.43 billion. During the same quarter in the previous year, the business posted $6.02 earnings per share. The business's revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts expect that Amgen Inc. will post 22.97 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen's dividend payout ratio is presently 62.65%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.